InnoCan Pharma Corp. (INNO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BioSyent, Inc.

Fennec Pharmaceuticals, Inc.

Knight Therapeutics, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Defence Therapeutics Inc

Arch Biopartners, Inc.

Cybin, Inc.

Mindset Pharma, Inc.

Why is InnoCan Pharma Corp. ?

The company has declared Positive results for the last 13 consecutive quarters

OPERATING CASH FLOW(Y) Highest at CAD -2.16 MM
NET SALES(HY) At CAD 19.32 MM has Grown at 59.1%
ROCE(HY) Highest at -38.58%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 2.27%, its profits have risen by 51.2%

Underperformed the market in the last 1 year

The stock has generated a return of 2.27% in the last 1 year, much lower than market (S&P/TSX 60) returns of 21.04%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is InnoCan Pharma Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

InnoCan Pharma Corp.

-54.44%

-0.22

87.97%

S&P/TSX 60

29.96%

1.43

14.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

107.90%

EBIT Growth (5y)

11.29%

EBIT to Interest (avg)

-3.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

4.57

Tax Ratio

56.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.24

EV to EBIT

-11.66

EV to EBITDA

-12.02

EV to Capital Employed

-7.31

EV to Sales

0.53

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-46.41%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 0.81 MM

RAW MATERIAL COST(Y)

Fallen by -0.62% (YoY

CASH AND EQV(HY)

Highest at CAD 20.21 MM

DEBT-EQUITY RATIO (HY)

Lowest at -150.99 %

-22What is not working for the Company

INTEREST(HY)

At CAD 0.01 MM has Grown at 102.92%

NET PROFIT(Q)

At CAD -2.23 MM has Fallen at -181.89%

OPERATING PROFIT(Q)

Lowest at CAD -1.66 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -17.69 %

PRE-TAX PROFIT(Q)

Lowest at CAD -1.52 MM

EPS(Q)

Lowest at CAD -0.6

Here's what is working for InnoCan Pharma Corp.

Operating Cash Flow

Highest at CAD 0.81 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Cash and Eqv

Highest at CAD 20.21 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -150.99 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -0.62% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for InnoCan Pharma Corp.

Interest

At CAD 0.01 MM has Grown at 102.92%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)

Pre-Tax Profit

At CAD -1.52 MM has Fallen at -1,189.44%

over average net sales of the previous four periods of CAD 0.14 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CAD MM)

Net Profit

At CAD -2.23 MM has Fallen at -181.89%

over average net sales of the previous four periods of CAD 2.72 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CAD MM)

Operating Profit

Lowest at CAD -1.66 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CAD MM)

Operating Profit Margin

Lowest at -17.69 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CAD -1.52 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CAD MM)

EPS

Lowest at CAD -0.6

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CAD)